Robots, AI, and Innovative Drugs: China’s New Export Powerhouses
China’s export landscape is undergoing a profound transformation. The country that once dominated global trade with clothing, furniture, and home appliances—and more recently with electric vehicles, lithium batteries, and solar panels—is now turning to a new generation of high-tech exports. According to CCTV News, robots, artificial intelligence products, and innovative drugs—dubbed the “New New Three” (新新三样)—saw dramatic export growth in the first half of 2026, positioning themselves as China’s next iconic export categories.
This shift represents the latest chapter in China’s decades-long industrial evolution. Analysts tracking the transition note that it mirrors the country’s broader move from labor-intensive manufacturing toward technology-intensive, innovation-driven production—a trajectory that now places Chinese companies at the frontier of three of the world’s most dynamic industries.
The Rise of Artificial Intelligence Exports
Perhaps the most striking transformation is occurring in artificial intelligence. Chinese AI supply chain products—including fiber optics, optical modules, and servers—now contribute more than 50 percent of all electromechanical product export growth, according to data compiled by CCTV News from financial media reports.
The scale of China’s AI capabilities is underscored by data from OpenRouter, which shows that Chinese large language models processed 36.11 trillion tokens in the third week of July 2026 alone, ranking first globally for 12 consecutive weeks.
Crucially, Chinese AI exports extend far beyond hardware. As CCTV News reports, AI going overseas “is no longer just selling software; it embeds a chain of ‘invisible digital capabilities’ including algorithm development, model invocation, and intelligent agent deployment.” In Peru, Chinese algorithms now optimize real-time port cargo loading, improving operational efficiency. In Southeast Asia, Chinese AI technology is helping small and medium enterprises bridge the digital divide through digital transformation tools. And in the Middle East, a desert AI computing center powered by Chinese liquid cooling technology is supporting the region’s transition from energy hub to digital hub.
Traditional trade statistics, analysts point out, struggle to capture the full scope of these “invisible” digital exports, meaning China’s AI-driven trade footprint may be significantly larger than official figures suggest.
Robots: From Demonstration to Production
Chinese robot exports have moved decisively from spectacle to substance. “Last year everyone was watching ‘can it move,’” CCTV News observed, citing financial media reports. “This year they’re asking ‘where has it been deployed’ and ‘how to mass produce it.’”
The numbers bear that out. In the first half of 2026, Chinese exports of cleaning robots and intelligent bionic robots totaled 180.9 billion yuan. Industrial robot exports reached 62.9 billion yuan, up 18.6 percent year-on-year, sold to 141 countries and regions. Most striking is the surgical robot category: exports surged 3.3 times year-on-year to 4.8 billion yuan, with destination markets expanding from 23 to 49 countries.
Behind these figures lies a manufacturing ecosystem of remarkable density. In Suzhou’s Wuzhong District, more than 1,600 upstream and downstream enterprises—producing radar, sensors, core motors, and other components—have clustered within a 10-kilometer supply chain radius, according to CCTV News reporting that cites regional financial media. One factory that began production in the first half of 2026 already has overseas orders booked through December.
The Yangtze River Delta region, a powerhouse of Chinese manufacturing, saw robot exports grow 1.2 times year-on-year. Chinese robot exports now form a complete “product ladder” spanning consumer robots, industrial robots, and frontier humanoid robots, giving Chinese manufacturers a presence in nearly every segment of the global robotics market.
Innovative Drugs: China’s Pharmaceutical Breakthrough
Perhaps the most unexpected export success story is in innovative pharmaceuticals. Chinese drug companies reported licensing-out deals totaling approximately $1.1 trillion in the first half of 2026, reaching 80 percent of the full-year 2025 total and setting a new record. The deals spanned 10 therapeutic areas—including oncology, metabolism, immunology, and neurology—with buyers in more than 20 countries including the United States, the United Kingdom, France, and Italy.
China’s National Medical Products Administration approved 38 new Class 1 innovative drugs in the first half of the year. Among these were 11 drugs with entirely new targets and mechanisms—all independently developed by domestic Chinese pharmaceutical companies. For context, only 11 such “global first” drugs received approval in all of 2025, and fewer than half of those were domestic Chinese developments.
China now accounts for approximately 30 percent of the global innovative drug pipeline, ranking second in the world. A telling milestone came with a new narcolepsy treatment—a selective orexin type 2 receptor agonist—that was first approved in China ahead of the United States, Japan, and the European Union. Industry watchers describe this as a shift from “China waiting for global approvals” to “global waiting for China’s approval.”
Geopolitical Pushback
The rapid rise of Chinese tech exports has not gone unnoticed abroad. On July 28, 2026, the Trump administration announced a ban on importing Chinese advanced robots and grid-tied inverters. According to Guancha (Observer), the US Federal Communications Commission updated its “restricted list” to include foreign-produced advanced robotics equipment—specifically humanoid and quadruped robots—citing concerns that “these devices could create supply chain vulnerabilities that undermine US economic and national security.”
Guancha reports that Morgan Stanley predicts the humanoid robot market could reach $5 trillion by 2050, suggesting the import ban may be as much about competitive positioning as national security. Critics have noted potential conflicts of interest, as Trump’s sons have invested in defense and robotics companies focused on US domestic production.
In response, a Chinese Foreign Ministry spokesperson stated: “China firmly opposes the US overstretching the concept of national security and creating various discriminatory lists to unjustifiably suppress Chinese companies. We urge the US to correct its wrong practices and stop its unreasonable suppression of Chinese companies.”
From ‘Old Three’ to ‘New New Three’: An Industrial Evolution
The emergence of the “New New Three” is best understood as the latest stage in a decades-long industrial journey. Decades ago, China’s “Old Three”—clothing, furniture, and home appliances—symbolized a manufacturing economy built on low-cost labor. These gave way to the “New Three”—electric vehicles, lithium batteries, and solar panels—which reflected China’s pivot to green technology and advanced manufacturing.
Now, as CCTV News frames it, robots, AI, and innovative drugs represent “the direction of future industries.” The Yangtze River Delta region alone achieved first-half 2026 exports of 9.62 trillion yuan, up 18 percent year-on-year—a record high that underscores the scale of this transition.
What to Watch
Several questions will define the trajectory of these new export sectors. First, how will the US-China tech decoupling dynamic evolve? The robot import ban may foreshadow broader restrictions, particularly as Chinese AI and pharmaceutical exports grow. Second, can Chinese pharmaceutical companies navigate lengthy overseas regulatory approval processes to convert licensing deals into sustained market access? Third, how sustainable is the growth in AI and robotics exports, particularly if global demand softens or competitors accelerate their own capabilities?
What is clear is that China’s export engine is no longer defined by what it can manufacture cheaply, but by what it can innovate at the frontier. The “New New Three” represent not just a shift in product categories, but a fundamental reorientation of China’s role in the global economy—from the world’s factory to the world’s high-tech laboratory.